Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer

Next Previous
X
Search
Trial Profile

A Two-arm Randomized Open Label Phase 2 Study Of Cp-751,871 In Combination With Exemestane Versus Exemestane Alone As First Line Treatment For Postmenopausal Patients With Hormone Receptor Positive Advanced Breast Cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Figitumumab (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer

    • Most Recent Events

    • 19 Aug 2016 This trial was completed in UK (end date; 10-06-2014) and Belgium according to European Clinical Trials Database.
    • 05 Jan 2015 According to European Clinical Trials Database record the trial is completed in Italy and Sweden; Whereas it is ongoing in Belgium and UK.
    • 11 Apr 2014 Planned End Date changed from 1 Mar 2015 to 1 May 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top